Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL

Roy, D -C; Lachance, S; Roy, J; Walker, I; Maertens, Johan; Cohen, S; Foley, SR; Lewalle, P; Olavarria, E; Selleslag, D; Ruediger, M; Velthuis, J; Reitsma, K; Gerez, L; Rovers, J; Boenig, H; Mielke, S

Bone Marrow Transplantation

Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL

Author:

Roy, D -C

Lachance, S ; Roy, J ; Walker, I ; Maertens, Johan ; Cohen, S ; Foley, SR ; Lewalle, P ; Olavarria, E ; Selleslag, D ; Ruediger, M ; Velthuis, J ; Reitsma, K ; Gerez, L ; Rovers, J ; Boenig, H ; Mielke, S

Keywords:

1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, Immunology

Bone Marrow Transplantation Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL

Author:

Keywords:

Bone Marrow Transplantation

Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL